TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05172219

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: System Sent Outreach with Embedded Asynchronous Care in Portal Message
Description: Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: System Sent Outreach without Embedded Asynchronous Care in Portal Message
Description: Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
Study: NCT00127270

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral therapy
Description: Behavioral Modification Programme for symptoms of overactive bladder
Study: NCT02102659

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Upper Limit Nutrition Support Therapy
Description: Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Formula Nutrition Support Therapy
Description: Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula.
Study: NCT04267900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-HPArk2
Description: 99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
Study: NCT01978938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study: NCT02184052

Intervention type: DRUG
Intervention: Meloxicam
Description: 7.5 mg or 15 mg
Study: NCT04455490

Intervention type: OTHER
Intervention: Self-control
Description: We compared relevant scores of patients before and after surgery
Study: NCT02032043

Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin MDA
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.

Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin MDA
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
Study: NCT03552250

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting for Lifelong Health for Young Children
Description: In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
Study: NCT04549883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theoretical practical educational session
Description: 1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
Study: NCT02209428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
Study: NCT02917018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
Study: NCT02004288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Protectis DSM17938
Description: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri Protectis DSM17938
Description: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
Study: NCT03154892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection
Description: Intracameral Conbercept injection for the treatment of NVG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Conbercept injection for the treatment of NVG
Study: NCT03353233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)
Study: NCT03205254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: four days of participant-scaled isocaloric Mediterranean meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: four days of participant-scaled isocaloric Mediterranean meals
Study: NCT03353233

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block
Description: An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
Study: NCT03205254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast food diet
Description: four days of participant-scaled isocaloric fast food meals
Study: NCT03353233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block
Description: An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
Study: NCT02285036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination PPV23
Description: All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccination PNEUMOVAX 23
Description: Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
Study: NCT01696682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrowed Gastric Conduit
Description: The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
Study: NCT01696682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Widened Gastric Conduit
Description: A widened gastric tube will be formed during the surgery
Study: NCT03725462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioskin
Description: Subjects have a monitoring with cardioskin and comparator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronaute
Description: Subjects have a monitoring with Neuronaute and comparator
Study: NCT04024501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad ER8 capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad A-capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad A-capsule formulation (fed)
Description: Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad B-capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad B-capsule formulation (fed)
Description: Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Study: NCT01698957

Intervention type: OTHER
Intervention: Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
Description: bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
Study: NCT00388947

Intervention type: DEVICE
Intervention: AMS Prolapse Product
Description: AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
Study: NCT03160560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Unflavored Rinse
Description: Subjects in Test group will receive ClōSYS® Unflavored Rinse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Flavored Rinse
Description: Subjects in Test group will receive ClōSYS® Flavored Rinse.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in Placebo group will receive Placebo Rinse.
Study: NCT03409822

Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo SpHb™ monitor
Description: Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
Study: NCT03118440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero-fluoroscopy 3D navigation
Description: Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional x-ray navigation
Description: Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
Study: NCT00403260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine - artesunate
Description: once a day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine plus artesunate
Description: once a day for 3 days
Study: NCT04574596

Intervention type: OTHER
Intervention: no Intervention
Description: This is an observational study. There is no intervention

Intervention type: OTHER
Intervention: no Intervention
Description: This is an observational study. There is no intervention
Study: NCT04406870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Product
Description: Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
Study: NCT01431092

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
Study: NCT03581461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Mindfulness-Based Yoga
Description: The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
Study: NCT03608150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia One
Description: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive Correction
Description: Standard of care refractive correction (ex. spectacles)
Study: NCT02834845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane %2-3 for general anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane %6-8 for general anesthesia maintenance
Study: NCT01090895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
Study: NCT01723644

Intervention type: OTHER
Group type: OTHER
Intervention: the clinical reassessment arm
Description: In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America

Intervention type: OTHER
Group type: OTHER
Intervention: the procalcitonin arm
Description: In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
Study: NCT06773442

Intervention type: OTHER
Intervention: Rehabilitation Practices Group
Description: Evidence-Based Training Program:Develop a structured training program for rehabilitation professionals focusing on evidence-based shoulder rehabilitation practices.~Clinical Mentorship and Supervision:Implement a mentorship program where experienced rehabilitation professionals provide guidance and support to junior staff members.~Standardization of Rehabilitation Protocols:Review and standardize rehabilitation protocols for common shoulder conditions based on current evidence and best practices.~Patient-Centered Care Approach:Adopt a patient-centered approach to shoulder rehabilitation, emphasizing shared decision-making and individualized treatment plans Outcome Monitoring and Quality Improvement:Use standardized outcome measures to evaluate improvements in pain, function, range of motion, and patient satisfaction.

Intervention type: OTHER
Intervention: Documentation Protocols Group
Description: Training and Education Program:Develop and implement a training program for rehabilitation professionals aimed at enhancing their knowledge and skills in shoulder rehabilitation practices and documentation protocols.~Standardization of Protocols:Review and update existing rehabilitation protocols to ensure alignment with current evidence-based guidelines and best practices.~Quality Assurance Measures:Establish a system for ongoing monitoring and evaluation of shoulder rehabilitation practices and documentation protocols.~Patient Education and Engagement:Develop educational materials and resources for patients undergoing shoulder rehabilitation to enhance their understanding of treatment goals, exercises, and self-management strategies.~Outcome Monitoring and Evaluation:Implement a system for monitoring and evaluating patient outcomes, including pain levels, range of motion, functional status, and satisfaction with rehabilitation services.
Study: NCT02207946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT02777528

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization Procedure
Description: Revascularization procedure of the great vessel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization Procedure
Description: Revascularization procedure of the great vessel
Study: NCT01777763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg
Study: NCT02595632

Intervention type: OTHER
Intervention: No intervention
Study: NCT03310307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: 50,000 IU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01777763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg
Study: NCT03667001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50mg NANO-efavirenz
Description: OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg NANO-Lopinavir
Description: BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg NANO-Lopinavir
Description: BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg Ritonavir
Description: BID
Study: NCT03667001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Study: NCT04444232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View an educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT00945360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Description: Letrozole at a dose of 2.5 mg/day for 8 weeks.